

SCHIZOPHRENIA Factsheet

October 2020

How is aggression and agitation relevant to schizophrenia?

Agitation and/or aggression are sometimes observed during a psychiatric emergency such as in onset of acute psychosis. Agitation typically includes irritability and restlessness, motor or verbal hyperactivity, uncooperativeness, and occasionally aggressive gestures or behaviour. This can pose a risk both to the individual, as well as the attending health care professionals, and so is important to manage this behaviour and prevent potential harm.

What is the evidence for treatments for aggression and agitation?

Moderate quality evidence found a small to medium-sized effect of less hostility with second-generation antipsychotics compared to first-generation antipsychotics, particularly when given in high doses (>500mg chlorpromazine equivalent).

For particular antipsychotics, moderate to high quality evidence found haloperidol was more effective than placebo for sedation, agitation, and mental state in the short term, but haloperidol induced more extrapyramidal symptoms. There were small benefits of aripiprazole over placebo for agitation and needing fewer additional injections, with no differences in side effects. Haloperidol had similar benefit to aripiprazole for aggression, but less need for an additional injection. Aripiprazole had less overall side effects than haloperidol.

Moderate quality evidence found olanzapine was more beneficial than haloperidol for sedation, agitation and adverse effects, particularly extrapyramidal symptoms. There was also less agitation and better global state with olanzapine compared to aripiprazole, although there was more somnolence with olanzapine. Haloperidol was more effective than risperidone for sedation and aggression but resulted in more akathisia. Ziprasidone had similar benefit to haloperidol for sedation and aggression but had fewer side effects. Droperidol resulted in less need for an additional injection than haloperidol. Moderate to low quality evidence found a medium-sized benefit of 5-10mg of aerosol loxapine for reducing agitation compared to inhaled placebo.

For combination therapies, moderate to low quality evidence found people receiving adjunctive benzodiazepines were more likely to be sedated for up to one hour, but were not less aggressive after one hour, than those on antipsychotics alone. Parkinsonism was lower and somnolence was higher with adjunctive benzodiazepines. Haloperidol plus promethazine was more effective than haloperidol alone for sedation and resulted in fewer overall adverse effects, particularly dystonia. Risperidone plus clonazepam resulted in more overall adverse effects than haloperidol, particular extrapyramidal symptoms, with no differences in sedation or agitation.

Neura Discover, Conquer, Cure

NeuRA (Neuroscience Research Australia) is one of the largest independent medical and clinical research institutes in Australia and an international leader in neurological research.

Diseases of the brain and nervous system pose the greatest health, economic and social burden of any disease group because they are chronic, debilitating and have no known cures.

Medical research is the cornerstone of efforts to advance the health and wellbeing of families and the community. Our dedicated scientists are focussed on transforming their research into significant and practical benefits for all patients.

While we hope you find this information useful, it is always important to discuss any questions about schizophrenia or its treatment with your doctor or other health care provider.

For more information see the technical table

HOW YOUR SUPPORT HELPS

We are able to make significant advances due to the generosity of countless people. Your donation allows us to continue to work towards transforming lives. For information on how you can support our research, phone 1300 888 019 or make a secure donation at neura.edu.au/donate/schizophrenia.